Researcher
Oswaldo Cruz Foundation, Brazil
I am an Infectious Diseases Physician, with master in Infectious Diseases and PhD in Public Health, and a Senior Researcher and Professor at Evandro Chagas National Institute of Infectious at Oswaldo Cruz Foundation (INI-Fiocruz). I am an accomplished translational scientist, who has been actively involved with the HIV epidemic for 33 years. Currently, I am in my forth four-year term as Director of INI-Fiocruz. I have served as Head of HIV care department at the Brazilian National HIV/AIDS Program at the Brazilian Ministry of Health and Director of the Rio de Janeiro State AIDS Program. I played a pivotal role in the establishment of INI-Fiocruz HIV service and in the concept and establishment of its cohorts (HIV women’s cohort, HIV Clinical cohort, Acute HIV infection cohort, and the Mpox cohort in 2022). I was the Brazilian PI of the Clinical Research Consortium established with UCLA, which comprised 7 Brazilian sites under my leadership, PI of HPTN 040/PACTG 1043, and site PI of iPrEX, iPrEX OLE, HPTN 085 (AMP), HPTN 095, and HVTN 706. I have served in HPTN and ACTG scientific committees, several protocol teams, and in the HPTN executive committee. I have conducted pivotal tuberculosis clinical trials, such as A5221 and A5279. I was part of the Brazilian task force that ruled out the association between potential neural tube defects and periconceptional DTG after the WHO warning. I was the PI of the TQT study, which evaluated the expansion of testing, quarantine, e-health and telemonitoring strategies to contribute to the COVID-19 response in Brazil. Currently, I am the Chair of ImPrEP, a UNITAID-funded implementation study of HIV PrEP for men who have sex with men (MSM) and transgender individuals at high risk for HIV infection in Brazil, Mexico and Peru, which enrolled 9,509 participants, and the Co-Chair of the ImPrEP CAB-LA Brasil Study, an implementation study of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis among young MSM, non-binary, and transgender persons. I am also the current PI of the A5384, a phase II, randomized, open-label trial of a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide versus a standard nine-month regimen for the treatment of adults and adolescents with tuberculous meningitis (IMAGINE-TBM). I am a key Brazilian investigator for the Caribbean, Central and South America network for HIV epidemiology (CCASAnet), which is a Regional Member of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). I am Faculty of the Master and PhD Degree Program on Clinical Research in Infectious Diseases at INI-Fiocruz.
Disclosure(s): No financial relationships to disclose
171 - STI Management in Latin America and the Caribbean: Emerging Trends and Future Challenges
Friday, October 18, 2024
3:15 PM – 4:30 PM US PT
406 - PrEP and Treatment of HIV in LATAM
Friday, October 18, 2024
3:40 PM – 4:05 PM US PT